0001062993-24-000923.txt : 20240116
0001062993-24-000923.hdr.sgml : 20240116
20240116190709
ACCESSION NUMBER: 0001062993-24-000923
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240116
FILED AS OF DATE: 20240116
DATE AS OF CHANGE: 20240116
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Quinlan Paul T
CENTRAL INDEX KEY: 0001333277
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36500
FILM NUMBER: 24536422
BUSINESS ADDRESS:
BUSINESS PHONE: 510-293-8123
MAIL ADDRESS:
STREET 1: C/O CYMABAY THERAPEUTICS, INC.
STREET 2: 7575 GATEWAY BLVD., SUITE 110
CITY: NEWARK
STATE: CA
ZIP: 94560
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CymaBay Therapeutics, Inc.
CENTRAL INDEX KEY: 0001042074
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 943103561
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7575 GATEWAY BOULEVARD
STREET 2: SUITE 110
CITY: NEWARK
STATE: CA
ZIP: 94560
BUSINESS PHONE: 510-293-8800
MAIL ADDRESS:
STREET 1: 7575 GATEWAY BOULEVARD
STREET 2: SUITE 110
CITY: NEWARK
STATE: CA
ZIP: 94560
FORMER COMPANY:
FORMER CONFORMED NAME: METABOLEX, INC.
DATE OF NAME CHANGE: 20090721
FORMER COMPANY:
FORMER CONFORMED NAME: METABOLEX INC
DATE OF NAME CHANGE: 19970710
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0508
4
2024-01-16
0001042074
CymaBay Therapeutics, Inc.
CBAY
0001333277
Quinlan Paul T
C/O CYMABAY THERAPEUTICS, INC.
7575 GATEWAY BLVD., SUITE 110
NEWARK
CA
94560
0
1
0
0
General Counsel
0
Common Stock
2024-01-16
4
M
0
5000
2.94
A
5000
D
Common Stock
2024-01-16
4
S
0
5000
23.5796
D
0
D
Employee Stock Option (right to buy)
2.94
2024-01-16
4
M
0
5000
0
D
2032-01-24
Common Stock
5000
107000
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.48 to $23.70, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2022.
/s/ Paul Quinlan
2024-01-16